ArticleClinical and experimental medicine2025
SMOC2 promotes peritoneal metastasis of gastric cancer involving Wnt/β-catenin pathway modulation and inducing angiogenesis.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, with peritoneal metastasis commonly seen in advanced cases. Based on RNA-sequencing data from GEO dataset, we focused on the role of SMOC2, SPARC-related modular calcium-binding protein 2, in regulating GC progression and peritoneal metastasis. Our analysis revealed that high SMOC2 expression was associated with poor survival in the population with peritoneal metastases. Functional assays demonstrated that SMOC2 promotes the migration and invasion of GC cells in vitro. In vivo experiments using a mouse peritoneal metastasis model showed that SMOC2 promoted the peritoneal metastasis of GC cells. Additionally, in a co-culture system of GC cells and endothelial cells, SMOC2 overexpression in GC cells promoted the proliferation, migration, and tube formation capability of endothelial cells. Mechanistically, SMOC2 knockdown reduced GSK-3β phosphorylation and nuclear β-catenin levels, accompanied by decreased expression of downstream target genes. These results indicate that SMOC2 promotes GC peritoneal metastasis involving Wnt/β-catenin pathway modulation. In conclusion, our findings highlight SMOC2's significant role in GC progression, potentially involving Wnt/β-catenin pathway modulation and angiogenesis. These results position SMOC2 as a potential prognostic biomarker and therapeutic target for GC peritoneal metastasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.